Cargando…
Comparison of the efficacy of two natural surfactants (BERAKSURF and BLES) in the treatment of respiratory distress syndrome among preterm neonates
BACKGROUND: The benefit of surfactant replacement therapy for respiratory distress syndrome (RDS) has been demonstrated. However, some surfactants are expensive and usually inaccessible. Consequently, the Iranian Survanta was produced, but its effect on complications and mortality of RDS is unknown....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691073/ https://www.ncbi.nlm.nih.gov/pubmed/38036980 http://dx.doi.org/10.1186/s12887-023-04406-2 |
_version_ | 1785152663186309120 |
---|---|
author | Sabzevari, Fatemeh Eslamian, Mahdie Karami Robati, Fatemeh Bahmanbijari, Bahareh Daei Parizi, Zahra Jamali, Zahra |
author_facet | Sabzevari, Fatemeh Eslamian, Mahdie Karami Robati, Fatemeh Bahmanbijari, Bahareh Daei Parizi, Zahra Jamali, Zahra |
author_sort | Sabzevari, Fatemeh |
collection | PubMed |
description | BACKGROUND: The benefit of surfactant replacement therapy for respiratory distress syndrome (RDS) has been demonstrated. However, some surfactants are expensive and usually inaccessible. Consequently, the Iranian Survanta was produced, but its effect on complications and mortality of RDS is unknown. This study aimed to compare the therapeutic outcomes of Iranian surfactant (beraksurf) and BLES (bovine lipid extract surfactant) on RDS treatment among preterm neonates. METHODS: This triple blinded randomized controlled trial study was performed on 128 eligible neonates diagnosed with RDS in Afzalipour hospital in Kerman, Iran. Diagnosis of RDS, gestational age of 28–34 weeks and weight ≥ 1 kg were considered as inclusion criteria. Congenital anomalies such as congenital cyanotic heart diseases, digestive system anomalies and chromosome abnormalities were the exclusion criteria Neonates were randomly assigned into two equal groups: (1) those treated with BLES (n = 64) and (2) those treated with beraksurf (n = 64). Complications including patent ductus arteriosus (PDA), sepsis, intraventricular hemorrhage (IVH), pneumothorax, pulmonary hemorrhage, mortality, and also, the number of days required for invasive mechanical ventilation (using ventilator) and non-invasive continuous positive airway pressure (CPAP) were evaluated for all neonates. The risk ratio (RR) was calculated at 95% of confidence intervals (CI). RESULTS: Compared with BLES group, the RR estimate among neonates in beraksurf group was 0.89 (0.66–1.20) for PDA, 0.71 (0.23–2.13) for IVH, 0.44 (0.14–1.36) for sepsis, 0.35 (0.13–0.93) for pneumothorax, 0.33 (0.12–0.86) for pulmonary hemorrhage, and 0.55 (0.28–1.05) for mortality. CONCLUSIONS: Despite advances in the use of exogenous surfactants for the treatment of neonatal respiratory distress syndrome; There are still some controversial topics in this field. The results obtained in the present study showed that the two types of surfactant (BERAKSURF and BLES) have similar efficacy for the treatment and short-term outcomes in preterm infants with respiratory distress syndrome. Therefore, due to the cost-effectiveness of BRAKSURF compared to BLES, We recommend choosing BERAKSURF in terms of treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-023-04406-2. |
format | Online Article Text |
id | pubmed-10691073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106910732023-12-02 Comparison of the efficacy of two natural surfactants (BERAKSURF and BLES) in the treatment of respiratory distress syndrome among preterm neonates Sabzevari, Fatemeh Eslamian, Mahdie Karami Robati, Fatemeh Bahmanbijari, Bahareh Daei Parizi, Zahra Jamali, Zahra BMC Pediatr Research BACKGROUND: The benefit of surfactant replacement therapy for respiratory distress syndrome (RDS) has been demonstrated. However, some surfactants are expensive and usually inaccessible. Consequently, the Iranian Survanta was produced, but its effect on complications and mortality of RDS is unknown. This study aimed to compare the therapeutic outcomes of Iranian surfactant (beraksurf) and BLES (bovine lipid extract surfactant) on RDS treatment among preterm neonates. METHODS: This triple blinded randomized controlled trial study was performed on 128 eligible neonates diagnosed with RDS in Afzalipour hospital in Kerman, Iran. Diagnosis of RDS, gestational age of 28–34 weeks and weight ≥ 1 kg were considered as inclusion criteria. Congenital anomalies such as congenital cyanotic heart diseases, digestive system anomalies and chromosome abnormalities were the exclusion criteria Neonates were randomly assigned into two equal groups: (1) those treated with BLES (n = 64) and (2) those treated with beraksurf (n = 64). Complications including patent ductus arteriosus (PDA), sepsis, intraventricular hemorrhage (IVH), pneumothorax, pulmonary hemorrhage, mortality, and also, the number of days required for invasive mechanical ventilation (using ventilator) and non-invasive continuous positive airway pressure (CPAP) were evaluated for all neonates. The risk ratio (RR) was calculated at 95% of confidence intervals (CI). RESULTS: Compared with BLES group, the RR estimate among neonates in beraksurf group was 0.89 (0.66–1.20) for PDA, 0.71 (0.23–2.13) for IVH, 0.44 (0.14–1.36) for sepsis, 0.35 (0.13–0.93) for pneumothorax, 0.33 (0.12–0.86) for pulmonary hemorrhage, and 0.55 (0.28–1.05) for mortality. CONCLUSIONS: Despite advances in the use of exogenous surfactants for the treatment of neonatal respiratory distress syndrome; There are still some controversial topics in this field. The results obtained in the present study showed that the two types of surfactant (BERAKSURF and BLES) have similar efficacy for the treatment and short-term outcomes in preterm infants with respiratory distress syndrome. Therefore, due to the cost-effectiveness of BRAKSURF compared to BLES, We recommend choosing BERAKSURF in terms of treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-023-04406-2. BioMed Central 2023-12-01 /pmc/articles/PMC10691073/ /pubmed/38036980 http://dx.doi.org/10.1186/s12887-023-04406-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Sabzevari, Fatemeh Eslamian, Mahdie Karami Robati, Fatemeh Bahmanbijari, Bahareh Daei Parizi, Zahra Jamali, Zahra Comparison of the efficacy of two natural surfactants (BERAKSURF and BLES) in the treatment of respiratory distress syndrome among preterm neonates |
title | Comparison of the efficacy of two natural surfactants (BERAKSURF and BLES) in the treatment of respiratory distress syndrome among preterm neonates |
title_full | Comparison of the efficacy of two natural surfactants (BERAKSURF and BLES) in the treatment of respiratory distress syndrome among preterm neonates |
title_fullStr | Comparison of the efficacy of two natural surfactants (BERAKSURF and BLES) in the treatment of respiratory distress syndrome among preterm neonates |
title_full_unstemmed | Comparison of the efficacy of two natural surfactants (BERAKSURF and BLES) in the treatment of respiratory distress syndrome among preterm neonates |
title_short | Comparison of the efficacy of two natural surfactants (BERAKSURF and BLES) in the treatment of respiratory distress syndrome among preterm neonates |
title_sort | comparison of the efficacy of two natural surfactants (beraksurf and bles) in the treatment of respiratory distress syndrome among preterm neonates |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691073/ https://www.ncbi.nlm.nih.gov/pubmed/38036980 http://dx.doi.org/10.1186/s12887-023-04406-2 |
work_keys_str_mv | AT sabzevarifatemeh comparisonoftheefficacyoftwonaturalsurfactantsberaksurfandblesinthetreatmentofrespiratorydistresssyndromeamongpretermneonates AT eslamianmahdie comparisonoftheefficacyoftwonaturalsurfactantsberaksurfandblesinthetreatmentofrespiratorydistresssyndromeamongpretermneonates AT karamirobatifatemeh comparisonoftheefficacyoftwonaturalsurfactantsberaksurfandblesinthetreatmentofrespiratorydistresssyndromeamongpretermneonates AT bahmanbijaribahareh comparisonoftheefficacyoftwonaturalsurfactantsberaksurfandblesinthetreatmentofrespiratorydistresssyndromeamongpretermneonates AT daeiparizizahra comparisonoftheefficacyoftwonaturalsurfactantsberaksurfandblesinthetreatmentofrespiratorydistresssyndromeamongpretermneonates AT jamalizahra comparisonoftheefficacyoftwonaturalsurfactantsberaksurfandblesinthetreatmentofrespiratorydistresssyndromeamongpretermneonates |